EUDA EUDA HEALTH HLDGS LTD

EUDA Health Holdings Limited Has Regained Compliance with Nasdaq Capital Market’s Continued Listing Requirements After receipt of Nasdaq Notification Regarding Minimum Market Value Deficiency

EUDA Health Holdings Limited Has Regained Compliance with Nasdaq Capital Market’s Continued Listing Requirements After receipt of Nasdaq Notification Regarding Minimum Market Value Deficiency

Singapore., Jan. 16, 2024 (GLOBE NEWSWIRE) -- As previously disclosed, EUDA Health Holdings Limited (“EUDA” and the “Company”) received a written notice from Nasdaq on January 9, 2024 indicating that the Company had failed to maintain a minimum market value of listed securities of $35 million over the previous 30 consecutive business days (the “MVLS Requirement”) as required by the Nasdaq Listing Rule 5550(b)(2).

On January 16, 2024, the Company received a written notice from Nasdaq stating that the Company’s Market Value of Listed Securities has been $35 million or greater for ten consecutive business days from January 2 to January 16, 2024, and therefore the Company has regained compliance with the MVLS requirement for continued listing on the Nasdaq Capital Market.

For investor and media inquiries, please contact:

Dr. Kelvin Chen

Chief Executive Officer

EUDA Health Holdings Limited



EN
16/01/2024

Underlying

EUDAEUDA HEALTH HLDGS LTD

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on EUDA HEALTH HLDGS LTD

 PRESS RELEASE
Free
EUDA EUDA HEALTH HLD...

EUDA Signs Letter of Intent to Potentially Acquire GO POSB

EUDA Signs Letter of Intent to Potentially Acquire GO POSB SINGAPORE, Sept. 10, 2025 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced that its wholly-owned subsidiary, EUDA Health Pte. Ltd. (“EUDA Health”), has signed a Letter of Intent (the “LOI”) to potentially acquire GO POSB Organoids Pte Ltd (“GO POSB”), a biotechnology company formed in Singapore. GO POSB has developed a proprietary induced pluripotent stem cell (iPSC) pla...

September 10, 2025 1 EN
 PRESS RELEASE
Free
EUDA EUDA HEALTH HLD...

EUDA Strategically Expands into T-Cell Immunotherapy – Strengthening I...

EUDA Strategically Expands into T-Cell Immunotherapy – Strengthening Its Stem Cell Therapy Portfolio SINGAPORE, Sept. 04, 2025 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (“EUDA” or the “Company”) (NASDAQ: EUDA), a leading Singapore-based non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia, and China, today announced that it has secured distribution rights for T-cell immunotherapies in Malaysia developed by Shenzhen Inno Immune Co. Ltd. (“Shenzhen Inno”), a developer of autologous cellular therapeutic and customized medicines for a wide range of diseases in ...

September 4, 2025 1 EN
 PRESS RELEASE
Free
EUDA EUDA HEALTH HLD...

EUDA Signs Letter of Intent to Potentially Acquire Chemokine Pte Ltd

EUDA Signs Letter of Intent to Potentially Acquire Chemokine Pte Ltd SINGAPORE, Aug. 28, 2025 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a leading Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced that it has signed a Letter of Intent (the “LOI”) to potentially acquire Chemokine Pte Ltd (“Chemokine”). EUDA will carry out due diligence on Chemokine, subject to confidentiality obligations. Chemokine has agreed to an exclusivity period of at least one hundred and twenty (120) d...

August 28, 2025 1 EN
 PRESS RELEASE
Free
EUDA EUDA HEALTH HLD...

EUDA Expands Wellness Product Portfolio With A Next-Generation Immune ...

EUDA Expands Wellness Product Portfolio With A Next-Generation Immune Health Supplement SINGAPORE, Aug. 26, 2025 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a leading Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced that its wholly-owned subsidiary, EUDA Health Pte. Ltd., has secured exclusive worldwide distribution rights for a next-generation immune health supplement (the “Supplement”) from Chemokine Pte. Ltd. (“Chemokine”), a Singapore-based biotech company focused on mole...

August 26, 2025 1 EN
 PRESS RELEASE
Free
EUDA EUDA HEALTH HLD...

EUDA Partners with Authorized Distributor of Guangdong Cell Biotech to...

EUDA Partners with Authorized Distributor of Guangdong Cell Biotech to Offer Stem Cell Therapies to Customers in Singapore and Malaysia SINGAPORE, April 24, 2025 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (“EUDA” or the “Company”) (NASDAQ: EUDA), a Singapore-based property management services provider and a leading non-invasive healthcare provider in Singapore and Malaysia, today announced an update to the potential strategic partnership, previously announced in December 2024, with Guangdong Cell Biotech Co. Ltd. (“Guangdong Cell Biotech”). Guangdong Cell Biotech is a prominent pla...

April 24, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch